生物制药公司Pharvaris N.V.（纳斯达克股票代码：PHVS）周二盘中股价大幅下跌8.82%，引发市场关注。虽然公司尚未正式发布财报，但投资者似乎对即将公布的业绩持悲观态度。
据悉，Pharvaris N.V.将于次日发布2024财年业绩报告。预览数据显示，公司2024财年净亏损达1.45亿美元，较上一财年亏损扩大33.03%。更值得注意的是，公司全年未能实现任何营收，每股基本亏损为2.69美元。这些数据反映出公司目前面临严峻的财务挑战，可能是导致投资者信心下降的主要原因。
尽管短期内公司股价承压，但Pharvaris N.V.作为一家专注于开发治疗遗传性血管性水肿（HAE）新药的后期生物制药公司，仍受到部分分析师的关注。目前有6家机构对其给出目标价预测，平均目标价为38.60美元，最高达55.14美元。公司正在进行关键的第三期临床试验，其研发进展可能会在未来影响投资者情绪。然而，在取得实质性突破之前，公司可能会继续面临财务压力和市场波动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.